GSK_Annual_Report_2021

Our COVID-19 response: Accelerating access. Delivering hope. Since the outbreak of the COVID-19 pandemic, GSK has stayed true to its purpose of helping people do more, feel better and live longer, and provided continued access to essential medicines that can make a life-saving difference. We prioritised the health and wellbeing of our colleagues and defied all odds to keep our manufacturing facilities and supply chain operating at full capacity, while also supporting healthcare systems and contributing to community relief efforts. During the year, we accelerated patients’ access to our portfolio, providing them with hope when they needed it the most. By adopting digital technologies, we ensured that our response to the ‘new normal’ is agile and effective. Driven by our purpose and patient-centricity, we responded to the crisis with swiftness by putting in place our business continuity processes with urgency. Through a set of coordinated actions, led by a central team, we protected employee health at the workplaces and ensured our manufacturing facilities remained safe. We harnessed Responding with agility improved technology and agile practices to keep our facilities operating to their full capacity throughout the year. Our on-time, in-full (OTIF) supply performance levels remained high, which enabled us to deliver on time, while complying with rigorous standards of product quality and safety management systems. 4 Company Overview GlaxoSmithKline Pharmaceuticals Limited